Chardan Capital Reaffirms “Hold” Rating for Novavax (NVAX)
Several other research firms have also issued reports on NVAX. Citigroup raised their price target on Novavax from $2.00 to $2.75 and gave the stock a neutral rating in a research report on Wednesday, February 21st. BidaskClub upgraded Novavax from a buy rating to a strong-buy rating in a research report on Wednesday, February 21st. B. Riley set a $10.00 price target on Novavax and gave the stock a buy rating in a research report on Thursday. Ladenburg Thalmann Financial Services restated a buy rating and issued a $3.50 price target on shares of Novavax in a research report on Thursday. Finally, Piper Jaffray Companies raised their price target on Novavax to $2.50 and gave the stock a neutral rating in a research report on Thursday. Two investment analysts have rated the stock with a sell rating, four have assigned a hold rating, three have given a buy rating and one has assigned a strong buy rating to the stock. The stock presently has an average rating of Hold and an average target price of $3.11.
Novavax (NVAX) traded down $0.13 during trading hours on Thursday, hitting $2.14. The stock had a trading volume of 17,390,000 shares, compared to its average volume of 11,970,000. Novavax has a 1-year low of $0.73 and a 1-year high of $2.75. The company has a debt-to-equity ratio of -4.28, a current ratio of 3.31 and a quick ratio of 3.31. The company has a market cap of $671.14, a price-to-earnings ratio of -3.15 and a beta of 2.49.
ILLEGAL ACTIVITY NOTICE: This report was reported by Daily Political and is the property of of Daily Political. If you are reading this report on another website, it was illegally stolen and republished in violation of U.S. & international copyright law. The correct version of this report can be read at https://www.dailypolitical.com/2018/03/04/chardan-capital-reaffirms-hold-rating-for-novavax-nvax.html.
Novavax, Inc is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company operates through developing recombinant vaccines segment. The Company, through its recombinant nanoparticle vaccine technology, produces vaccine candidates to respond to both known and newly emerging diseases.
Receive News & Ratings for Novavax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novavax and related companies with MarketBeat.com's FREE daily email newsletter.